- Source:
Publisher: Springer International Country of Publication: Germany NLM ID: 9103030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8491 (Electronic) Linking ISSN: 09401334 NLM ISO Abbreviation: Eur Arch Psychiatry Clin Neurosci Subsets: MEDLINE
- Publication Information:
Original Publication: Berlin ; New York : Springer International, c1990-
- Subject Terms:
- Abstract:
Competing Interests: Declarations. Conflict of interest: On behalf of all authors, the corresponding author states that there is no conflict of interest. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/00449 (to A Lladó) and co-funded by the European Union and CERCA Program/Generalitat de Catalunya. Albert Lladó also received funding from Departament de Salut – Generalitat de Catalunya (PERIS 2016–2020 SLT008/18/00061). Núria Guillén received funding by Instituto de Salud CarlosIII (ISCIII) through the project FI20/00076 and co-funded by the European Union. Gerard Piñol-Ripoll received fundind from the Government of Catalonia, Department of Health (PERIS 2019 SLT008/18/00050) and the IRBLleida-Diputació de Lleida (PIRS2021). Daniel Alcolea received funding from Institute of Health Carlos III (ISCIII), Spain PI18/00435 and INT19/00016, and the Department of Health Generalitat de Catalunya PERIS program SLT006/17/125. Alberto Lleó received research grants from CIBERNED (Program 1, Alzheimer Disease), Institute of Health Carlos III (PI17/01896 and AC19/00103), Generalitat de Catalunya (PERIS SLT002/16/408 and AGAUR), Fundació La Marató de TV3 (20142610) and Fundación BBVA. Juan Fortea received research grants from Institute of Health Carlos III (PI14/01126, PI17/01019 and PI20/01473), National Institutes of Health (1R01AG056850-01A1; R21AG056974; and R01AG061566), Fundació La Marató de TV3 (20141210), and Pla Estratègic de Recerca i Innovació en Salut (PERIS) SLT006/17/119. Mariateresa Buongiorno was supported by a grant awarded by Fundació Docència i Recerca MútuaTerrassa (2022). Ethical approval: Approval was obtained from the six centers Ethics Committees. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta 1-42 (Aβ 1-42 , A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for Aβ1-42 , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ 1-42 /Aβ 1-40 (n = 155), 88% for pTau181/Aβ 1-42 (n = 94) and 82% for tTau/Aβ 1-42 (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ 1-42 /Aβ 1-40 was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ 1-42 alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers.
(© 2023. The Author(s).)
- References:
Alzheimers Dement. 2014 Nov;10(6):844-52. (PMID: 24798886)
Clin Chem Lab Med. 2013 Dec;51(12):2311-7. (PMID: 23940064)
Alzheimers Dement. 2019 Feb;15(2):205-216. (PMID: 30347188)
Eur J Neurol. 2019 Aug;26(8):1098-1104. (PMID: 30793432)
J Alzheimers Dis. 2018;61(1):135-143. (PMID: 29154286)
J Neurol. 2019 Sep;266(9):2304-2311. (PMID: 31179518)
JAMA Neurol. 2015 May;72(5):571-81. (PMID: 25822737)
Ann Clin Transl Neurol. 2019 Sep;6(9):1815-1824. (PMID: 31464088)
Stroke. 2003 Aug;34(8):1907-12. (PMID: 12855825)
Brain. 2012 Jul;135(Pt 7):2126-39. (PMID: 22628162)
Alzheimers Dement. 2018 Nov;14(11):1460-1469. (PMID: 29501462)
PLoS One. 2014 Jun 24;9(6):e100784. (PMID: 24959687)
Biol Psychiatry. 2012 May 1;71(9):792-7. (PMID: 21679929)
Clin Chim Acta. 2019 May;492:62-68. (PMID: 30735665)
Eur J Nucl Med Mol Imaging. 2017 May;44(5):850-857. (PMID: 27966045)
Neurology. 2017 Jul 4;89(1):88-100. (PMID: 28592453)
Trends Pharmacol Sci. 2015 May;36(5):297-309. (PMID: 25840462)
Alzheimers Res Ther. 2022 Apr 26;14(1):60. (PMID: 35473631)
Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
Alzheimers Dement. 2015 Sep;11(9):1050-68. (PMID: 25457431)
Alzheimers Dement. 2018 Nov;14(11):1470-1481. (PMID: 29499171)
Clin Chim Acta. 2015 Sep 20;449:9-15. (PMID: 26141614)
J Alzheimers Dis. 2014;39(4):719-26. (PMID: 24254700)
Brain. 2011 Sep;134(Pt 9):2456-77. (PMID: 21810890)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
Neurology. 2020 Aug 4;95(5):e519-e531. (PMID: 32611641)
Alzheimers Dement. 2020 Jan;16(1):144-152. (PMID: 31914216)
Eur Arch Psychiatry Clin Neurosci. 2023 Feb;273(1):243-252. (PMID: 35710952)
Lancet Neurol. 2013 Feb;12(2):207-16. (PMID: 23332364)
J Alzheimers Dis. 2022;87(4):1659-1669. (PMID: 35723108)
J Neurochem. 2007 May;101(4):1053-9. (PMID: 17254013)
Neurology. 2011 Mar 15;76(11):1006-14. (PMID: 21325651)
Brain. 2016 Apr;139(Pt 4):1226-36. (PMID: 26936941)
Alzheimers Res Ther. 2022 Feb 1;14(1):20. (PMID: 35105351)
J Alzheimers Dis. 2016 May 6;52(4):1403-13. (PMID: 27163824)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):587-97. (PMID: 26253588)
Alzheimers Res Ther. 2017 Aug 9;9(1):60. (PMID: 28793924)
- Grant Information:
PI14/01126 Instituto de Salud Carlos III; PI17/01019 Instituto de Salud Carlos III; 1R01AG056850-01A1 Foundation for the National Institutes of Health; PI19/00449 Instituto de Salud Carlos III; R21AG056974 Foundation for the National Institutes of Health; PI20/01473 Instituto de Salud Carlos III; INT19/00016 Instituto de Salud Carlos III; 2022 Fundació Docència i Recerca Mútua de Terrassa; SLT006/17/119 Departament de Salut, Generalitat de Catalunya; AC19/00103 Instituto de Salud Carlos III; 20141210 Fundació la Marató de TV3; Alzheimer Disease Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas; Program 1 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas; PI18/00435 Instituto de Salud Carlos III; AGAUR Departament de Salut, Generalitat de Catalunya; FI20/00076 Instituto de Salud Carlos III; 20142610 Fundació la Marató de TV3; PIRS2021 Diputació de Lleida; PERIS SLT002/16/408 Departament de Salut, Generalitat de Catalunya; RF1 AG061566 United States AG NIA NIH HHS; PERIS 2016-2020 SLT008/18/00061 Departament de Salut, Generalitat de Catalunya; PERIS 2019 SLT008/18/00050 Departament de Salut, Generalitat de Catalunya; SLT006/17/125 Departament de Salut, Generalitat de Catalunya; PI17/01896 Instituto de Salud Carlos III; R01AG061566 Foundation for the National Institutes of Health
- Contributed Indexing:
Keywords: Alzheimer’s disease; Amyloid-PET; Biomarkers; CSF
- Accession Number:
0 (Amyloid beta-Peptides)
0 (tau Proteins)
0 (Biomarkers)
0 (Peptide Fragments)
0 (amyloid beta-protein (1-42))
0 (MAPT protein, human)
- Publication Date:
Date Created: 20231029 Date Completed: 20250205 Latest Revision: 20250428
- Publication Date:
20250429
- Accession Number:
PMC11799063
- Accession Number:
10.1007/s00406-023-01701-y
- Accession Number:
37898567
Processing Request
No Comments.